8. Teva Pharmaceutical Industries (TEVA) makes and sells generic drugs.
In October, Teva completed the acquisition of Cephalon for a total consideration of $6.15 billion in cash, as per data compiled by Bloomberg. Pursuant to the acquisition, each share of Cephalon common stock has been converted into the right to receive $81.50 in cash.Teva foresees realizing annual cost synergies of at least $500 million within three years of the transaction's closing. Non-GAAP diluted earnings per share for full year 2011 are estimated in the range of $4.92 to $5.02, including non-GAAP diluted earnings per share contribution of approximately 15 cents from the consolidation of the Cephalon acquisition. The acquisition is seen supporting Teva's long-term strategy of achieving more than $9 billion revenue in 2015, as compared to $4.6 billion in 2010. Of the 36 analysts covering the stock, 75% rate it a buy. On average, analysts polled by Bloomberg expect the stock to gain 29% to $53.77 in the coming 12 months. >>To see these stocks in action, visit the 8 Big Acquirers of 2011 portfolio on Stockpickr.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV